PuSH - Publication Server of Helmholtz Zentrum München: DNA-methylome–based tumor hypoxia classifier identifies HPV-negative head and neck cancer patients at risk for locoregional recurrence after primary radiochemotherapy.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Tawk, B.* ; Rein, K.* ; Schwager, C.* ; Knoll, M.* ; Wirkner, U.* ; Hörner-Rieber, J.* ; Liermann, J.* ; Kurth, I.* ; Balermpas, P.* ; Rödel, C.* ; Linge, A.* ; Löck, S.* ; Lohaus, F.* ; Tinhofer, I.* ; Krause, M.* ; Stuschke, M.* ; Grosu, A.L.* ; Zips, D.* ; Combs, S.E.* ; Belka, C. ; Stenzinger, A.* ; Herold-Mende, C.* ; Baumann, M.* ; Schirmacher, P.* ; Debus, J.* ; Abdollahi, A.*

DNA-methylome–based tumor hypoxia classifier identifies HPV-negative head and neck cancer patients at risk for locoregional recurrence after primary radiochemotherapy.

Clin. Cancer Res. 29, 3051-3064 (2023)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold (Paid Option)

Abstract
Metrics
Extra information

Purpose: Tumor hypoxia is a paradigmatic negative prognosticator of treatment resistance in head and neck squamous cell carcinoma (HNSCC). The lack of robust and reliable hypoxia classifiers limits the adaptation of stratified therapies. We hypothesized that the tumor DNA methylation landscape might indicate epigenetic reprogramming induced by chronic intratumoral hypoxia. Experimental Design: A DNA-methylome–based tumor hypoxia classifier (Hypoxia-M) was trained in the TCGA (The Cancer Genome Atlas)-HNSCC cohort based on matched assignments using gene expression–based signatures of hypoxia (Hypoxia-GES). Hypoxia-M was validated in a multicenter DKTK-ROG trial consisting of human papillomavirus (HPV)–negative patients with HNSCC treated with primary radiochemotherapy (RCHT). Results: Although hypoxia-GES failed to stratify patients in the DKTK-ROG, Hypoxia-M was independently prognostic for local recurrence (HR, 4.3; P ¼ 0.001) and overall survival (HR, 2.34; P ¼ 0.03) but not distant metastasis after RCHT in both cohorts. Hypoxia-M status was inversely associated with CD8 T-cell infiltration in both cohorts. Hypoxia-M was further prognostic in the TCGA-PanCancer cohort (HR, 1.83; P ¼ 0.04), underscoring the breadth of this classifier for predicting tumor hypoxia status. Conclusions: Our findings highlight an unexplored avenue for DNA methylation–based classifiers as biomarkers of tumoral hypoxia for identifying high-risk features in patients with HNSCC tumors.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Gene-expression Classifier; Good Prognosis Subgroups; Squamous-cell Carcinoma; Postoperative Radiochemotherapy; Marker Expression; Radiotherapy; Multicenter; Stanniocalcin-2; Interference; Metastasis

ISSN (print) / ISBN 1078-0432

e-ISSN 1557-3265

Journal Clinical Cancer Research

Quellenangaben Volume: 29, Issue: 16, Pages: 3051-3064

Publisher American Association for Cancer Research (AACR)

Publishing Place 615 Chestnut St, 17th Floor, Philadelphia, Pa 19106-4404 Usa

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Translational Metabolic Oncology (TMO)

Grants Zentrum fur Personalisierte Medizin
Dieter Morszeck Foundation
National Center for Tumor Diseases (NCT) Heidelberg Radiation Oncology Program
Helmholtz Cross-Program Initiative Personalized Medicine (iMed)
German Cancer Consortium (DKTK)